CCL5 and metabolic dysfunction-associated steatohepatitis: In phase II clinical trials, inhibition of CCL2 and CCL5 signaling through selective blockade of CCR2 and CCR5 receptors attenuated the signs of NASH, reduced the levels of circulating biomarkers of systemic inflammation, including high-sensitivity C-reactive protein, IL-6, fibrinogen, and IL-1ß, and counteracted the development of fibrosis [151].